ClinicalTrials.gg
WithdrawnNCT03192969Updated Jul 12, 2017

A Study to Evaluate Efficacy and Safety of Subcutaneous Abatacept With Steroid Treatment Compared to Steroid Treatment Alone in Adults With Giant Cell Arteritis (GCA)

A Phase 3 interventional study of Abatacept and Placebo in Giant Cell Arteritis, sponsored by Bristol-Myers Squibb. Withdrawn at 99 sites in 21 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2017-07-12.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Why this study was withdrawn
Business objectives have changed

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 35 studies in Giant Cell Arteritis with a site in United States — 8 open to participants now, 8 under way, 1 of them phase 3. Giant Cell Arteritis · United States.

Enrollment
20th of 20
0 · median 68
Started
2017
with 1 other
Phase 3
7 of 35
1 open now
Registered
19th of 35
by date
Lead sponsor
1 of 35
Bristol-Myers Squibb

Among the 35 studies in Giant Cell Arteritis with a site in United States, this one is the 20th largest by enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2017, is one of 7 in phase 3, and was the 19th registered.

Giant Cell Arteritis

149 studies on the registry are indexed under Giant Cell Arteritis; 49 are open to participants now.

Browse Giant Cell Arteritis studies →

Open to participants now

8 of the 35 studies in Giant Cell Arteritis with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 36 Giant Cell Arteritis studies recruiting now, 34 (94%) set no upper age limit and none (0%) stop at 75 or younger; 4 take children under 18; 9 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Giant Cell Arteritis with a site in United States, or all of them as a file.
02

Study summary

To investigate the safety and efficacy of abatacept with steroid treatment in comparison to steroid treatment alone in up to a 28 week taper of steroid treatment to sustain remission of Giant Cell Arteritis in adults.

03

Conditions studied

  • Giant Cell Arteritis

Browse trials for

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Inclusion Criteria:

  • New headache (new onset or new type of localized pain in the head)
  • Elevated ESR (≥ 50 mm/h by the Westergren method) or CRP ≥ 1 mg/dL
  • Temporal artery abnormality (i.e. temporal artery tenderness to palpation or decreased pulsation, unrelated to arteriosclerosis of cervical arteries)
  • Temporal artery showing vasculitis characterized by a predominance of mononuclear cell infiltration or granulomatous inflammation, usually with multinucleated giant cells
  • Large vessel biopsy showing vasculitis characterized by a predominance of mononuclear cell infiltration or granulomatous inflammation, usually with multinucleated giant cells or characteristic changes of large vessel stenosis or aneurysm secondary to GCA as seen by arteriography (Magnetic Resonance Imaging/ Magnetic Resonance Angiography), ultrasound (eg, halo sign on color duplex sonography), or CT scan
  • Patients must be treated with prednisone or prednisolone of 20-60 mg/day (prednisone equivalent) and be on a dose between 20-60 mg/day for at least 2 weeks prior to enrollment into the study

Exclusion criteria

Exclusion Criteria:

  • Rheumatic disease other than GCA such as Takayasu's Arteritis, granulomatosis with polyangiitis (Wegener's), rheumatoid arthritis, systemic lupus erythematosus
  • Patients with unilateral blindness (partial or complete) or who have unstable or recurrent visual symptoms attributable to GCA within 4 weeks of randomization
  • Patients with a history of dissection of aorta
  • Patients with a history of myocardial infarction, stroke or attributable to GCA within the 3 months of screening
  • Patients who have been treated with intravenous ("pulse") doses of defined as methylprednisolone > 1000 mg/day if given within 6 weeks of randomization
  • Patients who will require oral or IV glucocorticoid treatment during the trial for conditions other than GCA
  • Patients at risk of tuberculosis

Other protocol defined inclusion/exclusion criteria could apply

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Abatacept Combination Therapy

    Abatacept subcutaneous injection (125 mg/mL prefilled syringe weekly) in combination with glucocorticoid therapy (up to 28-week taper of oral prednisone daily)

    Drug: Abatacept · Drug: Glucocorticoid Treatment

  • Placebo comparator
    Placebo Monotherapy- 28 Weeks

    Glucocorticoid therapy (28-week taper of oral prednisone daily) in combination with placebo subcutaneous injection (1 mL pre-filled syringe weekly)

    Other: Placebo · Drug: Glucocorticoid Treatment

  • Placebo comparator
    Placebo Monotherapy- 52 Weeks

    Glucocorticoid therapy (52 week taper of oral prednisone daily) in combination with subcutaneous placebo weekly

    Other: Placebo · Drug: Glucocorticoid Treatment

Interventions

  • Abatacept subcutaneous injection, 125 mg/prefilled syringe (125 mg/mL)

  • OtherPlacebo

    Placebo for abatacept for subcutaneous injection in 1 mL pre-filled syringes

  • DrugGlucocorticoid Treatment

    Glucocorticoid taper (up to 52-week or 28-week of oral prednisone/prednisolone)

06

What researchers measure

Primary outcomes

  1. Patients in sustained remission

    Assessment based on 2-sided stratified Cochran-Mantel-Haenszel (CMH) chi-square test, stratified by baseline glucocorticoid dose group (20-\< 30, 30-\< 40, 40-\< 50 and 50-60 mg/day) and GCA diagnosis (New vs Relapse) at a 5% significance level. Remission is defined as the absence of clinical signs and symptoms of active disease attributable to GCA.

    Time frame: 40 weeks (week 12 to week 52)

Secondary outcomes

  1. Physician's Global Assessment of Disease Activity according to visual analog scale (VAS)

    measured by assessment parameters

    Time frame: Up to 52 weeks

  2. Subject Assessment of Disease Activity according to visual analog scale (VAS)

    measured by assessment parameters

    Time frame: Up to 52 weeks

  3. Short Form questionnaire-36 (SF-36)

    Patient reported outcome assessment

    Time frame: Up to 52 weeks

  4. Time from Week 12 to first relapse after achieving remission

    measured by investigator

    Time frame: 40 weeks (week 12 to week 52)

  5. Erythrocyte sedimentation rate (ESR)

    Mean change from baseline.

    Time frame: 52 weeks

  6. C-reactive protein (CRP)

    Mean change from baseline.

    Time frame: 52 weeks

  7. All adverse events and serious adverse events (AEs/SAEs)

    measured by incidence of AEs and SAEs

    Time frame: 52 weeks

  8. Laboratory test abnormalities

    measured by laboratory test parameters

    Time frame: 52 weeks

  9. Cmin (μg/mL): Trough level serum concentration of abatacept prior to the administration of the subcutaneous injection

    measured by serum concentration

    Time frame: 104 weeks

  10. Positive abatacept response relative to baseline

    A validated, sensitive, electrochemiluminescence assay (ECL) method will be used to analyze the presence of anti-abatacept antibodies in serum. Samples that are confirmed positive for antibodies specific to the CTLA4 region of abatacept will be further analyzed with a validated, in vitro, cell-based bioassay to determine whether the sera contained abatacept neutralizing activity.

    Time frame: 52 weeks

  11. Cumulative glucocorticoid dose

    measured as the total glucocorticoid dose used during the treatment period

    Time frame: 52 weeks

  12. EuroQOL 5 Dimensions (EQ-5D-3L)

    Patient reported outcome assessment

    Time frame: Up to 52 weeks

  13. Patient Reported Outcomes Measurement Information System (PROMIS)-Fatigue Short Form 8a

    Patient reported outcome assessment

    Time frame: Up to 52 weeks

  14. Resource Utilization

    Assessed by the number of hospitalizations

    Time frame: Up to 52 weeks

07

Study locations

99 sites
  • Local Institution
    Phoenix, Arizona 85032, United States
  • Local Institution
    Fullerton, California 92835, United States
  • Local Institution
    West Hollywood, California 90048, United States
  • Local Institution
    Denver, Colorado 80230, United States
  • Local Institution
    Iowa City, Iowa 52242, United States
  • Local Institution
    Kansas City, Kansas 66160, United States
  • Local Institution
    Rochester, Minnesota 55905-0001, United States
  • Local Institution
    New York, New York 10021, United States
  • Local Institution
    Cleveland, Ohio 44195, United States
  • Local Institution
    Dayton, Ohio 45417, United States
  • Local Institution
    Philadelphia, Pennsylvania 19104, United States
  • Local Institution
    Charleston, South Carolina 29406, United States
  • Local Institution
    Beaumont, Texas 77702, United States
  • Local Institution
    Northmead, New South Wales 2152, Australia
  • Local Institution
    Auchenflower, Queensland 4066, Australia
  • Local Institution
    Woodville South, South Australia 5001, Australia
  • Local Institution
    Malvern East, Victoria 3145, Australia
  • Local Institution
    Nedlands, Western Australia 6009, Australia
  • Local Institution
    Victoria Park, Western Australia 6100, Australia
  • Local Institution
    Graz, 8036, Austria
  • Local Institution
    Stockerau, 2000, Austria
  • Local Institution
    Leuven, 3000, Belgium
  • Local Institution
    Li?ge, 4000, Belgium
  • Local Institution
    Yvoir, 5530, Belgium
  • Local Institution
    Sofia, Sofia-grad 1606, Bulgaria
  • Local Institution
    Hamilton, Ontario L8N 4A6, Canada
  • Local Institution
    Trois-Rivieres, Quebec G8Z 1Y2, Canada
  • Local Institution
    Saskatoon, Saskatchewan S7K 0H6, Canada
  • Local Institution
    Aarhus C, 8000, Denmark
  • Local Institution
    Esbjerg, 6700, Denmark
  • Local Institution
    Glostrup, 2600, Denmark
  • Local Institution
    Holstebro, DK-7500, Denmark
  • Local Institution
    Odense C, 5000, Denmark
  • Local Institution
    Silkeborg, DK-8600, Denmark
  • Local Institution
    Tallinn, 11312, Estonia
  • Local Institution
    Tallinn, EE-13419, Estonia
  • Local Institution
    Tartu, 50107, Estonia
  • Local Institution
    Marseille, 13385, France
  • Local Institution
    Nantes, 44093, France
  • Local Institution
    Paris Cedex 14, 75679, France
  • Local Institution
    Paris, 75018, France
  • Local Institution
    Pau, 64000, France
  • Local Institution
    Toulouse, 31059, France
  • Local Institution
    Berlin, 13125, Germany
  • Local Institution
    Berlin, 14050, Germany
  • Local Institution
    Dresden, 01277, Germany
  • Local Institution
    Freiburg im Breisgau, 79095, Germany
  • Local Institution
    Hamburg, 22767, Germany
  • Local Institution
    Hannover, D30625, Germany
  • Local Institution
    Herne, 44652, Germany
  • Local Institution
    Kirchheim, 73230, Germany
  • Local Institution
    Rostock, 18059, Germany
  • Local Institution
    Tubingen, 72076, Germany
  • Local Institution
    W?rzburg, 97080, Germany
  • Local Institution
    Athens, 11527, Greece
  • Local Institution
    Larissa, 41110, Greece
  • Local Institution
    Thessaloniki, 56429, Greece
  • Local Institution
    Dublin, Ireland
  • Local Institution
    Catania, 95124, Italy
  • Local Institution
    Genova, 16132, Italy
  • Local Institution
    Milano, 20121, Italy
  • Local Institution
    Milano, 20132, Italy
  • Local Institution
    Milano, 20157, Italy
  • Local Institution
    Padova, 35128, Italy
  • Local Institution
    Pavia, 27100, Italy
  • Local Institution
    Prato, 51900, Italy
  • Local Institution
    Torino, 10126, Italy
  • Local Institution
    Almelo, 7609 PP, Netherlands
  • Local Institution
    Enschede, 7513 ER, Netherlands
  • Local Institution
    Groningen, 9713 GZ, Netherlands
  • Local Institution
    Helmond, 5707 HA, Netherlands
  • Local Institution
    Rotterdam, 3059XN, Netherlands
  • Local Institution
    Bydgoszcz, 85-168, Poland
  • Local Institution
    Krakow, 31-501, Poland
  • Local Institution
    Szczecin, 71-252, Poland
  • Local Institution
    Warszawa, 02-637, Poland
  • Local Institution
    Wroclaw, 52-416, Poland
  • Local Institution
    Cluj-Napoca, 400006, Romania
  • Local Institution
    Sibiu, 550245, Romania
  • Local Institution
    Belgrade, 11000, Serbia
  • Local Institution
    Barcelona, 08025, Spain
  • Local Institution
    Bilbao, 48013, Spain
  • Local Institution
    L'Hospitalet de Llobregat, 08907, Spain
  • Local Institution
    La Laguna, 38320, Spain
  • Local Institution
    Madrid, 28007, Spain
  • Local Institution
    Madrid, 28034, Spain
  • Local Institution
    Madrid, 28040, Spain
  • Local Institution
    Vitoria, 01009, Spain
  • Local Institution
    Stockholm, SE-18288, Sweden
  • Local Institution
    Uppsala, 755 92, Sweden
  • Local Institution
    V?ster?s, 72189, Sweden
  • Local Institution
    Basel, 4031, Switzerland
  • Local Institution
    Bern, 3010, Switzerland
  • Local Institution
    Freiburg, 1708, Switzerland
  • Local Institution
    St. Gallen, 9007, Switzerland
  • Local Institution
    Z?rich, 8091, Switzerland
  • Local Institution
    Westcliff-on-Sea, Essex SS0 0RY, United Kingdom
  • Local Institution
    Newcastle upon Tyne, Tyne and Wear NE7 7DN, United Kingdom
  • Local Institution
    London, E1 1BB, United Kingdom
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2017; primary completion for Jun 2020, 34 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2017
First posted
Jun 20, 2017
StartEst.
Jul 15, 2017
Primary completionEst.
Jun 7, 2020
CompletionEst.
Nov 23, 2021
Last update
Jul 12, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 12, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03192969
Responsible party
Sponsor
First posted
Jun 20, 2017
Start date
Jul 15, 2017 (estimated)
Primary completion
Jun 7, 2020 (estimated)
Completion
Nov 23, 2021 (estimated)
Last update
Jul 12, 2017

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abatacept

Start the discussion